BioSyntech is developing BST-Gel®-based injectable products which can deliver biotherapeutics to their targeted site of action.

Pacligel: is a BST-Gel® product for the sustained release of paclitaxel at tumor sites to prevent local tumor recurrence, for the treatment of breast and prostate cancers.

Cerebragel: is a BST-Gel® product for the sustained drug release at tumor sites, for the treatment of brain cancer.

Other applications in various fields, such as gynecology, growth factor therapies, etc are explored with partners under confidentiality agreements.